Micro-costing analysis from Italian Guidelines for the management of sporadic primary hyperparathyroidism.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ilaria Valentini, Basile Michele, Vescini Fabio, Borretta Giorgio, Chiodini Iacopo, Boniardi Marco, Carotti Marina, Castellano Elena, Cipriani Cristiana, Eller-Vainicher Cristina, Giannini Sandro, Iacobone Maurizio, Salcuni Antonio Stefano, Saponaro Federica, Spiezia Stefano, Versari Annibale, Zavatta Guido, Mitrova Zuzana, Saulle Rosella, Giovanazzi Alexia, Novizio Roberto, Paoletta Agostino, Papini Enrico, Persichetti Agnese, Samperi Irene, Scoppola Alessandro, Calò Pietro Giorgio, Cetani Filomena, Cianferotti Luisella, Corbetta Sabrina, De Rimini Maria Luisa, Falchetti Alberto, Laureti Stefano, Lombardi Celestino Pio, Madeo Bruno, Marcocci Claudio, Mazzaferro Sandro, Miele Vittorio, Minisola Salvatore, Palermo Andrea, Pepe Jessica, Scillitani Alfredo, Grimaldi Franco, Cozzi Renato, Attanasio Roberto
Аннотация
METHODS: A micro-costing approach was used to estimate the costs of surgical and non-surgical treatments. Data were gathered through a survey among panel members responsible for the Italian PHPT treatment guidelines, ensuring alignment with national clinical practice. The survey examined various cost components, including diagnostic tests, pre-hospitalization assessments, surgery duration, drug use, healthcare professionals involved, disposable materials, and follow-up care requirements.
RESULTS: The total cost for PHPT diagnosis and comorbidity assessment is € 887.96. Parathyroidectomy (PTX) costs € 4,588.00. Non-surgical alternatives, including pharmacological treatment (€ 953.34 annually) and active surveillance (€ 197.42 annually), result in cumulative 30-year costs of € 28,590 and € 5,910, respectively. Since PTX is typically performed at age 55, pharmacological treatment over 30 years incurs an additional € 22,876 per patient compared to surgery.
CONCLUSIONS: Despite its higher upfront cost, PTX demonstrated long-term cost efficiency due to the relatively low rates of follow-up complications and the absence of recurring annual costs associated with conservative strategies.